Immune Checkpoint Inhibitors in the Curative Setting: Pre-clinical and Clinical Data
(2023) Critical Issues in Head and Neck Oncology Key Concepts from the Eighth THNO Meeting — ISBN: [978-3-031-23174-2], 365, published
Files
978-3-031-23175-9_11.pdf
Open Access - Adobe PDF
- 233.29 KB
Details
- Authors
- Abstract
- Pembrolizumab and nivolumab, two monoclonal antibodies (mAbs) targeting programmed cell death protein-1 (PD-1), improve the overall survival of patients with inoperable recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). For curable HNSCC, the role of immunotherapy is under investigation. In this chapter, we briefly review the current use of immunotherapy with surgery or radio(chemo)therapy in the treatment of HNSCC with curative intent.
- Affiliations
Citations
Beyaert, S., Honoré, N., & Machiels, J.-P. (2023). Immune Checkpoint Inhibitors in the Curative Setting: Pre-clinical and Clinical Data. In Jan B. Vermorken, Volker Budach, C. René Leemans, Jean-Pascal Machiels, Piero Nicolai, Brian O’Sullivan (éd.) (ed.), Critical Issues in Head and Neck Oncology Key Concepts from the Eighth THNO Meeting (p. 365). https://doi.org/10.1007/978-3-031-23175-9_11